$351 Million is the total value of venBio Partners LLC's 9 reported holdings in Q2 2022. The portfolio turnover from Q1 2022 to Q2 2022 was 25.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| HRMY | Sell | HARMONY BIOSCIENCES HLDGS IN | $70,654,000 | -6.0% | 1,448,720 | -6.2% | 20.12% | +20.8% |
| PHVS | Sell | PHARVARIS N V | $50,862,000 | +21.8% | 2,301,451 | -0.1% | 14.48% | +56.4% |
| ELEV | Sell | ELEVATION ONCOLOGY INC | $2,613,000 | -60.2% | 1,866,339 | -28.4% | 0.74% | -48.9% |
| CMPI | Exit | CHECKMATE PHARMACEUTICALS IN | $0 | – | -3,673,374 | -100.0% | -2.60% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-08-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| VERONA PHARMA PLC | 15 | Q2 2022 | 22.2% |
| AKERO THERAPEUTICS INC | 14 | Q3 2022 | 65.3% |
| ALX ONCOLOGY HLDGS INC | 13 | Q3 2023 | 73.8% |
| HARMONY BIOSCIENCES HLDGS IN | 13 | Q3 2023 | 21.1% |
| APELLIS PHARMACEUTICALS INC | 11 | Q2 2021 | 62.0% |
| PHARVARIS N V | 11 | Q3 2023 | 25.2% |
| IMPEL PHARMACEUTICALS INC | 10 | Q3 2023 | 7.3% |
| ELEVATION ONCOLOGY INC | 10 | Q3 2023 | 4.2% |
| VENTYX BIOSCIENCES INC | 8 | Q3 2023 | 42.7% |
| PRECISION BIOSCIENCES INC | 7 | Q3 2020 | 62.0% |
View venBio Partners LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
View venBio Partners LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.